Analysts Anticipate Evotec AG (EVTCY) to Post $0.07 Earnings Per Share
Evotec AG (NASDAQ:EVTCY) has received a consensus broker rating score of 2.00 (Buy) from the two analysts that provide coverage for the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a hold recommendation and one has given a strong buy recommendation to the company.
Zacks has also assigned Evotec AG an industry rank of 120 out of 265 based on the ratings given to related companies.
A number of equities analysts have recently issued reports on EVTCY shares. Deutsche Bank AG reiterated a “neutral” rating on shares of Evotec AG in a research report on Wednesday, May 3rd. DZ Bank AG restated a “sell” rating on shares of Evotec AG in a report on Wednesday, July 12th. Finally, Berenberg Bank restated a “buy” rating on shares of Evotec AG in a report on Wednesday, May 10th.
Evotec AG (EVTCY) traded down 1.81% on Tuesday, reaching $30.87. 1,285 shares of the company’s stock traded hands. Evotec AG has a 52-week low of $9.18 and a 52-week high of $33.13. The firm’s 50 day moving average price is $30.50 and its 200 day moving average price is $23.11. The firm has a market capitalization of $2.16 billion and a PE ratio of 52.32.
COPYRIGHT VIOLATION WARNING: “Analysts Anticipate Evotec AG (EVTCY) to Post $0.07 Earnings Per Share” was first reported by American Banking News and is owned by of American Banking News. If you are accessing this article on another domain, it was stolen and reposted in violation of international copyright & trademark law. The legal version of this article can be accessed at https://www.americanbankingnews.com/2017/08/08/analysts-anticipate-evotec-ag-evtcy-to-post-0-07-earnings-per-share.html.
Evotec AG Company Profile
Evotec AG is a drug discovery and development company. The Company operates through two segments. The EVT Execute segment provides standalone drug discover services on a typical fee-for-service basis or integrated drug discovery collaborations on partners’ target through a range of commercial structures, including research fees, milestones and/or royalties.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Evotec AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec AG and related companies with MarketBeat.com's FREE daily email newsletter.